Sotiburafusp alfa

Multispecific antibody

Also known as HB0025

Phase 3planned

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational trial registered, not yet recruiting

No completed mid-stage readout is on record. Registrational readout expected around 2028-04-10.

Also in development:Endometrial Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Endometrial Cancer
NCT07902999 · Shanghai Huaota Biopharmaceutical Co., Ltd.
2026-10-20 – 2031-06-26 · First-line pMMR Endometrial Cancer
What this study did
Non-Small Cell Lung Cancer
Phase 2 (2)
Other / comorbidity
NCT07376629 · Huabo Biopharm Co., Ltd.
2025-08-14 – 2027-01-15 · TNBC
What this study did
NCT06222125 · Huabo Biopharm Co., Ltd.
2023-01-30 – 2025-12-30 · Renal Cancer
What this study did
Phase 1/2 (1)
Non-Small Cell Lung Cancer
Phase 1 (1)
Other / comorbidity
NCT04678908 · Huabo Biopharm Co., Ltd.
2021-03-10 – 2024-05-23 · Tumor, Subjects
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Endometrial Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sotiburafusp Alfa: this drugPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
DostarlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
SerabelisibPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
IMGN-151Phase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sotiburafusp alfa to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
January 2027 (1)
Phase 2TNBCEnrolling by invitation
Est. primary completion 2027-01-15 · NCT07376629 · CT.gov ↗
What to watch
2028 (2)
April 2028 (2)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04-10 · NCT07360132 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04-10 · NCT07383116 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-04-23 · NCT07902999 · CT.gov ↗
What to watch

See the full readout calendar ↗